KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Consolidated Net Income: 2018-2025

Historic Consolidated Net Income for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -$32.0 million.

  • Esperion Therapeutics' Consolidated Net Income fell 2.90% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.8 million, marking a year-over-year decrease of 160.12%. This contributed to the annual value of -$4.8 million for FY2024, which is 97.74% up from last year.
  • Per Esperion Therapeutics' latest filing, its Consolidated Net Income stood at -$32.0 million for Q3 2025, which was down 139.04% from -$13.4 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Consolidated Net Income ranged from a high of $58.2 million in Q1 2024 and a low of -$90.9 million during Q1 2021.
  • Moreover, its 3-year median value for Consolidated Net Income was -$32.0 million (2025), whereas its average is -$27.8 million.
  • In the last 5 years, Esperion Therapeutics' Consolidated Net Income soared by 192.46% in 2024 and then tumbled by 171.30% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Consolidated Net Income (Quarterly) stood at -$69.1 million in 2021, then rose by 17.69% to -$56.8 million in 2022, then declined by 1.02% to -$57.4 million in 2023, then soared by 63.71% to -$20.8 million in 2024, then fell by 2.90% to -$32.0 million in 2025.
  • Its last three reported values are -$32.0 million in Q3 2025, -$13.4 million for Q2 2025, and -$41.5 million during Q1 2025.